|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wolpin BM, Meyerhardt JA, Mamon HJ and
Mayer RJ: Adjuvant treatment of colorectal cancer. CA Cancer J
Clin. 57:168–185. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Storli KE, Søndenaa K, Bukholm IR, Nesvik
I, Bru T, Furnes B, Hjelmeland B, Iversen KB and Eide GE: Overall
survival after resection for colon cancer in a national cohort
study was adversely affected by TNM stage, lymph node ratio,
gender, and old age. Int J Colorectal Dis. 26:1299–1307. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stanford Cancer Center. Cancer diagnosis,
. Information about cancer. https://stanfordhealthcare.org/medical-clinics/cancer-center.htmlAccessed.
October 15–2008.
|
|
5
|
Schimanski CC, Frerichs K, Rahman F,
Berger M, Lang H, Galle PR, Moehler M and Gockel I: High miR-196a
levels promote the oncogenic phenotype of colorectal cancer cells.
World J Gastroenterol. 15:2089–2096. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Luo X, Stock C, Burwinkel B and Brenner H:
Identification and evaluation of plasma microRNAs for early
detection of colorectal cancer. PLoS One. 8:e628802013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Duffy MJ, van Dalen A, Haglund C, Hansson
L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C and Topolcan O:
Clinical utility of biochemical markers in colorectal cancer:
European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer.
39:718–727. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bandrés E, Cubedo E, Agirre X, Malumbres
R, Zárate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzó M, et
al: Identification by real-time PCR of 13 mature microRNAs
differentially expressed in colorectal cancer and non-tumoral
tissues. Mol Cancer. 5:292006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamamichi N, Shimomura R, Inada K, Sakurai
K, Haraguchi T, Ozaki Y, Fujita S, Mizutani T, Furukawa C,
Fujishiro M, et al: Locked nucleic acid in situ hybridization
analysis of miR-21 expression during colorectal cancer development.
Clin Cancer Res. 15:4009–4016. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lanza G, Ferracin M, Gafà R, Veronese A,
Spizzo R, Pichiorri F, Liu CG, Calin GA, Croce CM and Negrini M:
mRNA/microRNA gene expression profile in microsatellite unstable
colorectal cancer. Mol Cancer. 6:542007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schepeler T, Reinert JT, Ostenfeld MS,
Christensen LL, Silahtaroglu AN, Dyrskjøt L, Wiuf C, Sørensen FJ,
Kruhøffer M, Laurberg S, et al: Diagnostic and prognostic microRNAs
in stage II colon cancer. Cancer Res. 68:6416–6424. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K,
Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs
in serum: A novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Etheridge A, Lee I, Hood L, Galas D and
Wang K: Extracellular microRNA: A new source of biomarkers. Mutat
Res. 717:85–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ng EK, Chong WW, Jin H, Lam EK, Shin VY,
Yu J, Poon TC, Ng SS and Sung JJ: Differential expression of
microRNAs in plasma of patients with colorectal cancer: A potential
marker for colorectal cancer screening. Gut. 58:1375–1381. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Faltejskova P, Bocanek O, Sachlova M,
Svoboda M, Kiss I, Vyzula R and Slaby O: Circulating miR-17-3p,
miR-29a, miR-92a and miR-135b in serum: Evidence against their
usage as biomarkers in colorectal cancer. Cancer Biomark.
12:199–204. 2012.PubMed/NCBI
|
|
17
|
Chen Y, Gao SG, Chen JM, Wang GP, Wang ZF,
Zhou B, Jin CH, Yang YT and Feng XS: Serum CA242, CA199, CA125,
CEA, and TSGF are biomarkers for the efficacy and prognosis of
cryoablation in pancreatic cancer patients. Cell Biochem Biophys.
2014.
|
|
18
|
Hammarström S: The carcinoembryonic
antigen (CEA) family: Structures, suggested functions and
expression in normal and malignant tissues. Semin Cancer Biol.
9:67–81. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Monzo M, Navarro A, Bandres E, Artells R,
Moreno I, Gel B, Ibeas R, Moreno J, Martinez F, Diaz T, et al:
Overlapping expression of microRNAs in human embryonic colon and
colorectal cancer. Cell Res. 18:823–833. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shi B, SeppLorenzino L, Prisco M, Linsley
P, deAngelis T and Baserga R: Micro RNA 145 targets the insulin
receptor substrate-1 and inhibits the growth of colon cancer cells.
J Biol Chem. 282:32582–32590. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maestranzi S, Przemioslo R, Mitchell H and
Sherwood RA: The effect of benign and malignant liver disease on
the tumour markers CA19-9 and CEA. Ann Clin Biochem. 35:99–103.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Q, Huang Z, Ni S, Xiao X, Xu Q, Wang
L, Huang D, Tan C, Sheng W and Du X: Plasma miR-601 and miR-760 are
novel biomarkers for the early detection of colorectal cancer. PLoS
One. 7:e443982012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cheng H, Zhang L, Cogdell DE, Zheng H,
Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR and Zhang W:
Circulating plasma miR-141 is a novel biomarker for metastatic
colon cancer and predicts poor prognosis. PLoS One. 6:e177452011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schetter AJ, Leung SY, Sohn JJ, Zanetti
KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, et
al: MicroRNA expression profiles associated with prognosis and
therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436.
2008. View Article : Google Scholar : PubMed/NCBI
|
